In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed Impella 2.5 and 5.0:

This article was originally published in Clinica

Executive Summary

Abiomed has received Canadian approval for its Impella 2.5 and Impella 5.0 ventricular cardiac assist devices for maintaining circulatory support. The devices are inserted minimally invasively into the left ventricle, where they help pump blood in heart failure patients. The Danvers, Massachusetts company has already CE marked the Impella 2.5 for sale in Europe, and Abiomed has now completed enrolment in a pilot study of the technology in the US. The Impella 5.0, which can also be inserted surgically, is CE-marked too, and is in pilot studies in the US.

You may also be interested in...



Bleach Mixtures Return To US Regulatory Radar Making COVID-19 Treatment Claims

FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.

New China Drug Regulation Legalizes Emergency Approval Mechanism

The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.

3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

Topics

UsernamePublicRestriction

Register

MT049346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel